Effect of nalbuphine on patient controlled intravenous analgesia after radical resection of colon cancer.

Effect of nalbuphine on patient-controlled intravenous analgesia (PCIA) after radical resection of colon cancer was explored. Retrospective analyses of 100 patients who underwent elective laparoscopic radical resection of colon cancer in Xiang Yang No. 1 People's Hospital, Hubei University of Medicine from June 2014 to December 2016 were made. Forty-seven patients were treated with nalbuphine as experimental group and 53 cases were treated with morphine as control group. All patients received PCIA after surgery. According to visual analogue scale (VAS), pain degree at 2, 4, 8, 12 and 24 h after surgery, total dosage of analgesia pump, total times and effective times of pressing were evaluated. Analgesic satisfaction rate, and adverse reactions such as nausea, vomiting, dizziness and headache at the same time were observed and recorded. The postoperative VAS in the experimental group was evidently lower than that in the control group (P<0.05) at 8, 12 and 24 h after surgery, which was statistically significant. There was no significant difference in postoperative VAS between experimental group and control group at 2 and 4 h after surgery (P>0.05). The incidence of adverse reactions to nausea and vomiting in the experimental group was low. There was no significant difference in the total dosage of analgesia pump, total times and effective times of pressing and analgesic satisfaction rate (P>0.05). After laparoscopic radical resection of colon cancer, nalbuphine is effective in PCIA, with low incidence of adverse reactions and high safety.